Thyrocare

Tests you can trust

November 24, 2026

To,

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051
Symbol: THYROCARE

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001
Scrip Code: 539871

Dear Sir / Madam,

Subject: Change in Senior Management Personnel – Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**Listing Regulations**"), we wish to inform you that the Board of Directors of Thyrocare Technologies Limited (the "**Company**"), on the recommendation of the Nomination and Remuneration Committee, has approved the following changes in the Senior Management Personnel ("**SMP**") of the Company, on November 24, 2026, as follows:

1. **Mr. Sarovar Chandra** has been designated as Chief Technology Officer of the Company and identified as SMP of the Company.
2. **Mr. Piyush Singh**, Vice President – B2B Operations, has ceased to be SMP of the Company.

The aforesaid changes are limited to the SMP classification of the above personnel and do not affect their employment status or existing terms of service with the Company.

The aforesaid changes were approved by the Board by way of a resolution passed by circulation on **November 24, 2026,** at **02:58 P.M. (IST).**

The details required under SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed as **Annexure A**.

This intimation will also be made available on the website of the Company at https://investor.thyrocare.com/announcements/.

We request you to take the above on record.

Yours faithfully,
For Thyrocare Technologies Limited

Brijesh Kumar

Digitally signed by Brijesh Kumar
Date: 2026.11.24 15:06:36 +05'30'

Thyrocare Technologies Limited

Brijesh Kumar
Company Secretary & Compliance Officer
ICSI Membership No.: A36070

Encl.: As above

Thyrocare

Tests you can trust

Annexure A

Details under Para A of Part A of Schedule III of the Listing Regulations read with SEBI Master Circular dated January 30, 2026

S. No.	Particulars	Mr. Sarovar Chandra	Mr. Piyush Singh
1.	Name and designation	Mr. Sarovar Chandra, Chief Technology Officer	Mr. Piyush Singh, Vice President – B2B Operations
2.	Reason for change, viz. appointment, re-appointment, resignation, removal, death or otherwise	Designated as Chief Technology Officer and identified as SMP, being the head of the technology function of the Company.	Cessation as SMP, as he no longer falls within the definition of "Senior Management" under Regulation 16(1)(d) of the Listing Regulations. He continues in the employment of the Company in his present role.
3.	Date of appointment / re-appointment / cessation (as applicable) and term of appointment / re-appointment	**Date of designation and identification as SMP:** November 24, 2026 **Term:** Not applicable	**Date of cessation as SMP:** November 24, 2026 **Term:** Not applicable
4.	Brief profile (in case of appointment)	Mr. Sarovar Chandra has more than 16 years of experience in technology, product and analytics. He has been with API Group, which owns and operates PharmEasy, Thyrocare, Ascent Wellness, Aknamed and Docon, since June 2017, most recently as Vice President – Product & Analytics. Within the Group, he has held several roles at PharmEasy and Thyrocare, including AVP and VP – Product & Technology. Before joining API Group, he was a Senior Product Manager at Razorpay and CouponDunia, and a Senior Software Developer at Skiva Technologies. He began his career as a Software Programmer at The Research Foundation for SUNY, New York. He studied Computer Engineering at the State University of New York, Stony Brook.	Not applicable
5.	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Sarovar Chandra is not related to any Director of the Company.	Not applicable